GENNEX LABORATORIES LTD.
Latest filings
- Gennex Laboratories 41st AGM: All 4 resolutions passed with over 99.8% majority · Board & Shareholder Meetings
- Gennex Labs appoints Dipankar Dasgupta as Independent Director · Management Changes
- Gennex Labs 41st AGM held on Sep 30, 2026; four resolutions transacted · Board & Shareholder Meetings
Snapshot
What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹173 Cr over the trailing twelve months.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from GENNEX LABORATORIES LTD.'s filed financials and exchange disclosures
What does GENNEX LABORATORIES LTD. do?
GENNEX LABORATORIES LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.
Is GENNEX LABORATORIES LTD. profitable?
Yes. Over the trailing twelve months GENNEX LABORATORIES LTD. reported a net profit of ₹21 Cr on revenue of ₹173 Cr.
Does GENNEX LABORATORIES LTD. pay a dividend?
Not in the latest reported year — GENNEX LABORATORIES LTD.'s dividend payout for FY26 was nil.
Is GENNEX LABORATORIES LTD. debt-free?
No. It reported borrowings of ₹36 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹36 Cr after cash. Debt stands at 0.15× equity. That is lower than 50% of its 166 Pharmaceuticals peers.
Is GENNEX LABORATORIES LTD. expensive compared with its peers?
On trailing P/E, GENNEX LABORATORIES LTD. ranks 26 of 158 in Pharmaceuticals — cheaper than 84% of them, against an industry median of 31.2×. This is a position, not a valuation judgement.
How much does the GENNEX LABORATORIES LTD. share price move in a day?
On a typical session GENNEX LABORATORIES LTD. moves 1.53% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
Where can I track GENNEX LABORATORIES LTD.'s announcements?
Every NSE and BSE filing by GENNEX LABORATORIES LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.